Attached files
| file | filename |
|---|---|
| EX-99.2 - EX-99.2 - VIROPHARMA INC | a13-17761_1ex99d2.htm |
| EX-99.1 - EX-99.1 - VIROPHARMA INC | a13-17761_1ex99d1.htm |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): August 1, 2013
VIROPHARMA INCORPORATED
(Exact Name of Registrant as Specified in its Charter)
|
DELAWARE |
|
0-021699 |
|
23-2789550 |
730 STOCKTON DRIVE, EXTON, PENNSYLVANIA 19341
(Address of Principal Executive Offices including Zip Code)
(610) 458-7300
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17CFR240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act(17CFR240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act(17CFR240.13e-4(c))
Item 2.02 Results of Financial Operations and Financial Condition.
On August 1, 2013, ViroPharma Incorporated (the “Company”) issued a press release announcing its financial results for its second quarter and six months ended June 30, 2013. In its press release, the Company included certain historical non-U.S. Generally Accepted Accounting Principles (“non-GAAP”) financial measures as defined in Regulation G promulgated by the Securities and Exchange Commission for each of the three-month and six-month periods ended June 30, 2013 and June 30, 2012 and as of June 30, 2013. Reconciliations for such historical non-GAAP financial measures are attached to or included in the press release furnished as Exhibit 99.1. The Company believes that its presentation of historical non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. These historical non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with U.S. Generally Accepted Accounting Principles.
Item 8.01. Other Events.
On August 1, 2013, the Company issued a press release to announce that, following discussions with the Center for Biologics Evaluation and Research (CBER) division of the U.S. Food and Drug Administration, the Company is going to discontinue its Phase 2 study of the combination of Cinryze® (C1 esterase inhibitor [human]) and recombinant human hyaluronidase enzyme (rHuPH20). The discontinuation of the study is a precaution related to the emergence of and unexpected incidence and titer of non-neutralizing anti-rHuPH20 antibodies in a number of patients with the formulation being used in this study.
The full text of a press release issued by the Company in connection with the announcement is set forth as Exhibit 99.2 attached hereto.
Item 9.01 Financial Statements and Exhibits.
The following exhibits are attached to this Form 8-K:
|
(d) |
Exhibit No. |
|
Description |
|
|
|
|
|
|
|
99.1 |
|
Press release dated August 1, 2013 announcing financial results. |
|
|
99.2 |
|
Press release dated August 1, 2013 announcing the discontinuation of the Company’s Phase 2 study of the combination of Cinryze (C1 esterase inhibitor [human]) and rHuPH20. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
VIROPHARMA INCORPORATED | |
|
|
| |
|
|
| |
|
Date: August 1, 2013 |
By: |
/s/ J. Peter Wolf |
|
|
|
J. Peter Wolf |
|
|
|
Vice President, General Counsel and Secretary |